<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">HIV AIDS (Auckl)</journal-id><journal-title-group><journal-title>HIV/AIDS (Auckland, N.Z.)</journal-title></journal-title-group><issn pub-type="epub">1179-1373</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22096382</article-id><article-id pub-id-type="pmc">3218704</article-id><article-id pub-id-type="publisher-id">hiv-2-027</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Is it safe? Talking to teens with HIV/AIDS about death and dying: a 3-month evaluation of Family Centered Advance Care (FACE) planning &#x02013; anxiety, depression, quality of life</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lyon</surname><given-names>Maureen E</given-names></name><xref ref-type="aff" rid="af1-hiv-2-027">1</xref><xref ref-type="corresp" rid="c1-hiv-2-027"/></contrib><contrib contrib-type="author"><name><surname>Garvie</surname><given-names>Patricia A</given-names></name><xref ref-type="aff" rid="af2-hiv-2-027">2</xref></contrib><contrib contrib-type="author"><name><surname>Briggs</surname><given-names>Linda</given-names></name><xref ref-type="aff" rid="af3-hiv-2-027">3</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Jianping</given-names></name><xref ref-type="aff" rid="af4-hiv-2-027">4</xref></contrib><contrib contrib-type="author"><name><surname>Malow</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="af5-hiv-2-027">5</xref></contrib><contrib contrib-type="author"><name><surname>D&#x02019;Angelo</surname><given-names>Lawrence J</given-names></name><xref ref-type="aff" rid="af1-hiv-2-027">1</xref></contrib><contrib contrib-type="author"><name><surname>McCarter</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="af4-hiv-2-027">4</xref></contrib></contrib-group><aff id="af1-hiv-2-027"><label>1</label>Children&#x02019;s National Medical Center and George Washington School of Medicine and Health Sciences, Washington, District of Columbia</aff><aff id="af2-hiv-2-027"><label>2</label>St Jude Children&#x02019;s Research Hospital, Memphis, Tennessee</aff><aff id="af3-hiv-2-027"><label>3</label>Gundersen Lutheran Medical Foundation, Inc., Madison, Wisconsin</aff><aff id="af4-hiv-2-027"><label>4</label>Children&#x02019;s Research Institute, Washington, District of Columbia</aff><aff id="af5-hiv-2-027"><label>5</label>Florida International University, Miami, Florida</aff><author-notes><corresp id="c1-hiv-2-027">Correspondence: Maureen E Lyon, Center for Clinical and Community, Research, Children&#x02019;s Research Institute, George Washington University Medical, School, Children&#x02019;s National Medical, Center, Room 658, 111 Michigan Avenue, N.W., Washington, D.C. 20010-2970, USA, Tel +1 202 476 5442, Fax +1 202 476 3630, Email <email>mlyon@cnmc.org</email></corresp></author-notes><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>18</day><month>2</month><year>2010</year></pub-date><volume>2</volume><fpage>27</fpage><lpage>37</lpage><permissions><copyright-statement>&#x000a9; 2010 Lyon et al, publisher and licensee Dove Medical Press Ltd</copyright-statement><copyright-year>2010</copyright-year><license><license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>To determine the safety of engaging HIV-positive (HIV+) adolescents in a Family Centered Advance Care (FACE) planning intervention.</p></sec><sec><title>Patients and methods</title><p>We conducted a 2-armed, randomized controlled clinical trial in 2 hospital-based outpatient clinics from 2006&#x02013;2008 with HIV+ adolescents and their surrogates (n = 76). Three 60&#x02013;90 minutes sessions were conducted weekly. FACE intervention groups received: Lyon FCACP Survey<sup>&#x000a9;</sup>, the Respecting Choices<sup>&#x000ae;</sup> interview, and completion of The Five Wishes<sup>&#x000a9;</sup>. The Healthy Living Control (HLC) received: Developmental History, Healthy Tips, Future Planning (vocational, school or vocational rehabilitation). Three-month post-intervention outcomes were: completion of advance directive (Five Wishes<sup>&#x000a9;</sup>); psychological adjustment (Beck Depression, Anxiety Inventories); quality of life (PedsQL<sup>&#x02122;</sup>); and HIV symptoms (General Health Self-Assessment).</p></sec><sec><title>Results</title><p>Adolescents had a mean age, 16 years; 40% male; 92% African-American; 68% with perinatally acquired HIV, 29% had AIDS diagnosis. FACE participants completed advance directives more than controls, using time matched comparison (<italic>P</italic> &#x0003c; 0.001). Neither anxiety, nor depression, increased at clinically or statistically significant levels post-intervention. FACE adolescents maintained quality of life. FACE families perceived their adolescents as worsening in their school (<italic>P</italic> = 0.018) and emotional (<italic>P</italic> = 0.029) quality of life at 3 months, compared with controls.</p></sec><sec><title>Conclusions</title><p>Participating in advance care planning did not unduly distress HIV+ adolescents.</p></sec></abstract><kwd-group><kwd>adolescents</kwd><kwd>advance care planning</kwd><kwd>communication</kwd><kwd>decision-making</kwd><kwd>family intervention</kwd><kwd>HIV/AIDS</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Most youth with HIV are now expected to live past 21 years,<xref ref-type="bibr" rid="b1-hiv-2-027">1</xref>,<xref ref-type="bibr" rid="b2-hiv-2-027">2</xref> yet mortality rates are 30 times higher than for the general US pediatric population.<xref ref-type="bibr" rid="b3-hiv-2-027">3</xref> In 2006, in a perinatally infected cohort the mean age of death was 18 years.<xref ref-type="bibr" rid="b4-hiv-2-027">4</xref> Overwhelming infection due to immune system compromise contributes to morbidity.<xref ref-type="bibr" rid="b4-hiv-2-027">4</xref> Thus, incorporating advance care planning during the &#x0201c;antecedent period of decision making&#x0201d;<xref ref-type="bibr" rid="b5-hiv-2-027">5</xref> may be valuable in preparing for end-of-life (EOL) care. Quality advance care planning includes discussing death, but differs from advance directives<xref ref-type="bibr" rid="b6-hiv-2-027">6</xref> (ie, documenting who you want to make health care decisions for you when you can&#x02019;t make them for yourself, the kind of medical treatment you want or do not want). Concern about possible emotional distress has impeded families<xref ref-type="bibr" rid="b7-hiv-2-027">7</xref>,<xref ref-type="bibr" rid="b8-hiv-2-027">8</xref> and providers from initiating conversations regarding EOL for teens living with a life-threatening condition.<xref ref-type="bibr" rid="b9-hiv-2-027">9</xref> Yet, talking about death and dying and decision-making with such teens may benefit them and their families.<xref ref-type="bibr" rid="b10-hiv-2-027">10</xref>&#x02013;<xref ref-type="bibr" rid="b12-hiv-2-027">12</xref> Teens want involvement in their own EOL decisions.<xref ref-type="bibr" rid="b13-hiv-2-027">13</xref> Guidelines<xref ref-type="bibr" rid="b11-hiv-2-027">11</xref>,<xref ref-type="bibr" rid="b14-hiv-2-027">14</xref> recommend conversations about advance care planning: 1) begin early or at diagnosis of a life-threatening condition; 2) be shared among the adolescent, family and health care provider; and 3) be routine and structured. Goals for EOL care frequently are unfulfilled, partially, because providers are concerned that talking about death and dying can provoke negative moods in the teen,<xref ref-type="bibr" rid="b15-hiv-2-027">15</xref> as well as families.<xref ref-type="bibr" rid="b11-hiv-2-027">11</xref>,<xref ref-type="bibr" rid="b12-hiv-2-027">12</xref> Our goal was to develop/adapt a structured, safe intervention that would provide an opportunity to talk about death and dying while medically stable: planning for the worst, hoping for the best.</p><p>Guided by a community-based participatory research framework,<xref ref-type="bibr" rid="b16-hiv-2-027">16</xref> the Family Centered Advance Care (FACE) planning development and proximal outcomes are reported elsewhere.<xref ref-type="bibr" rid="b17-hiv-2-027">17</xref>,<xref ref-type="bibr" rid="b18-hiv-2-027">18</xref> This report presents the 3-month FACE post-intervention outcomes: plans and actions, psychological adjustment, and quality of life. The FACE intervention is based on Leventhal&#x02019;s theory of self-regulation<xref ref-type="bibr" rid="b19-hiv-2-027">19</xref>&#x02013;<xref ref-type="bibr" rid="b21-hiv-2-027">21</xref> and Folkman and Lazarus&#x02019;s theory of transactional stress and coping<xref ref-type="bibr" rid="b22-hiv-2-027">22</xref> (See <xref ref-type="fig" rid="f1-hiv-2-027">Figure 1</xref>), postulating that interventions can change the appraisal of an illness from a death threat to a challenge with potential for growth and mastery.</p><p>We hypothesized that at 3 months, post-intervention families in the FACE intervention study would be significantly more likely to: 1) complete an advance directive (AD); 2) maintain or have improved psychological adjustment; 3) maintain or have enhanced quality of life; and 4) maintain or decrease HIV symptom severity, compared to families in the Healthy Living Control (HLC) time-matched comparison.</p></sec><sec sec-type="methods"><title>Patients and methods</title><sec sec-type="subjects"><title>Participants</title><p>Between July 1, 2006 and May 31, 2008, 40 HIV-infected adolescents and 40 adult surrogates (n = 80) were recruited from the Children&#x02019;s National Medical Center (CNMC) and St. Jude Children&#x02019;s Research Hospital (SJCRH) outpatient adolescent HIV specialty clinics. Recruitment criteria for adolescents included: aged 14&#x02013;21 years, with an available legal guardian (if under 18 years) or adult surrogate at least 21 years old who knew the adolescent&#x02019;s HIV status, not in foster care, no developmental delays, severe depression, suicidal or homicidal ideation, dementia or psychosis.<xref ref-type="bibr" rid="b23-hiv-2-027">23</xref>&#x02013;<xref ref-type="bibr" rid="b26-hiv-2-027">26</xref> Additional family members were permitted to participate, however, their data were excluded from analyses. The FACE study was Institutional Review Board approved at both institutions. All participants provided written assent/consent.</p></sec><sec><title>FACE intervention and healthy living control (HLC)</title><p>Full details of the study methods are reported elsewhere.<xref ref-type="bibr" rid="b17-hiv-2-027">17</xref>,<xref ref-type="bibr" rid="b18-hiv-2-027">18</xref> In brief, three 60&#x02013;90 minute semi-structured family interview sessions were conducted by a trained/certified interviewer at weekly intervals: <bold>Session 1</bold>: Lyon Advance Care Planning Survey<sup>&#x000a9;</sup> &#x02013; Adolescent and Surrogate Versions: <bold>Session 2:</bold> The Respecting Choices Interview<sup>&#x000ae;</sup> <bold>Session 3:</bold> Completion of The Five Wishes.<sup>&#x000a9;</sup></p><p>HLC subjects were also administered in three weekly 60&#x02013;90 minute sessions and family format to control for time, attention and/or related Hawthorn effects. <bold>Session 1:</bold> Developmental History.<xref ref-type="bibr" rid="b27-hiv-2-027">27</xref> <bold>Session 2:</bold> Safety Tips.<xref ref-type="bibr" rid="b28-hiv-2-027">28</xref> <bold>Session 3:</bold> School and Career Planning interview.<xref ref-type="bibr" rid="b29-hiv-2-027">29</xref></p></sec><sec><title>Outcome measures</title><p><bold>Five Wishes</bold><bold><sup>&#x000a9;</sup></bold> (Towey and Aging with Dignity) is a legal document that facilitates expression of treatment preferences, if they were unable to communicate their wishes and includes the selection of a surrogate decision-maker. It can also serve as a tool to facilitate the participation of adolescents under age 18,<xref ref-type="bibr" rid="b30-hiv-2-027">30</xref> but must be signed by their parent/legal guardian to be legally sufficient.</p><p><bold>Statement of Treatment Preferences</bold><xref ref-type="bibr" rid="b31-hiv-2-027">31</xref> expresses values and goals related to future decision making regarding frequently occurring scenarios common to individuals with complications of AIDS.<xref ref-type="bibr" rid="b32-hiv-2-027">32</xref> It was used to document specific treatment preferences of patients and their surrogates&#x02019; understanding of what the patient would want. Patients and surrogates chose one of three options, &#x0201c;to continue all treatment and keep fighting,&#x0201d; &#x0201c;to stop all treatment to prolong my life,&#x0201d; and &#x0201c;don&#x02019;t know.&#x0201d;</p><p><bold>Beck Anxiety Index</bold> (BAI)<xref ref-type="bibr" rid="b24-hiv-2-027">24</xref> is a 21-item measure of anxiety rated on a 4-point Likert scale of symptoms over the past week. The BAI has demonstrated adequate reliability and validity to clinically assess anxiety in individuals aged 17 to 80. We extended downward to age 14 to allow for consistency of data collected by a single measure of anxiety.</p><p><bold>Beck Depression Inventory-II</bold><xref ref-type="bibr" rid="b25-hiv-2-027">25</xref> is a 21-item scale self-report measure to assess presence of symptoms of depression over the past two weeks on a 4-point Likert scale for adolescents &#x0003e;13 years of age.</p><p><bold>The Pediatric Quality of Life Inventory</bold><bold><sup>&#x02122;</sup></bold> <bold>4.0</bold><xref ref-type="bibr" rid="b33-hiv-2-027">33</xref>&#x02013;<xref ref-type="bibr" rid="b35-hiv-2-027">35</xref> is a 23-item modular measure of health-related quality of life in children and adolescents. Four dimensions of functional quality of life (physical, emotional, social, school) are assessed. It has the strongest norms, validity, and reliability of the measures available. Norms exist for up to age 18.9 years, which was extended upward to allow for one assessment measure across participants.</p><p><bold>General Health Assessment for Children</bold><xref ref-type="bibr" rid="b36-hiv-2-027">36</xref> is a self-report measure for adolescents aged 12&#x02013;20 years. The HIV-related symptom subscale was used to assess the degree of distress caused by HIV-related physical symptoms. It is comprised of 18 items rated on a six-point Likert scale (&#x0201c;Not at All&#x0201d; to &#x0201c;Extremely&#x0201d;).</p><p>Measures were administered separately to both the adolescent and surrogate, at baseline and at the 3-month post-intervention follow-up.</p><p><bold>Stage of Illness</bold> was measured by the CDC (Centers for Disease Control and Prevention) classification system in place at the time of the study.<xref ref-type="bibr" rid="b37-hiv-2-027">37</xref></p></sec><sec sec-type="methods"><title>Study design/data collection</title><p>Adolescent/surrogate dyads were randomly assigned to one of two study groups, FACE versus HLC. Randomization utilized permuted block design, based on study site, to ensure the same numbers would be recruited to FACE and HLC. All participants were given a brochure with information on advance care planning and received standard of care. Follow-up data were collected face-to-face at 3-months post-intervention with two exceptions. A research assistant, not the facilitator, administered follow-up questionnaires orally to control for literacy. Progress of participants through the trial is illustrated in <xref ref-type="fig" rid="f2-hiv-2-027">Figure 2</xref>.</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>To assess whether the FACE intervention participants established an advance directive, medical charts were reviewed for documented completion.</p><p>Before we implemented parametric analyses, we evaluated the normality and variance homogeneity assumptions and when necessary implemented data transformations to ensure the data met these assumptions. Following analyses involving data transformations, the results were back transformed to return the estimates to their original scale and units. In this event, adjusted means are reported which also control for baseline levels of scores.</p><p>To evaluate changes in psychological adjustment and quality of life, ANCOVA (analysis of covariance) was used to estimate and compare group means, with 95% confidence intervals, by study group and assess the effect of the two groups. Each estimate was derived controlling for baseline anxiety and depression scores, as well as any covariates found in preliminary analyses to differ between groups. The slope coefficient for group was used to estimate the magnitude of any differences. A <italic>t</italic>-test was employed to assess statistical significance.</p><p>In secondary analyses, logistic regression models were used to test for a trend in the outcome based on the level of severity of illness using CDC criteria.<xref ref-type="bibr" rid="b37-hiv-2-027">37</xref> It was unnecessary to code for intervention exposure, because all subjects attended 100% of Sessions 1&#x02013;3. Estimates were derived separately for surrogate and adolescent. However, when possible, overall estimates were derived by treating the dyad as a cluster, again controlling for baseline levels, as well as any covariates found in preliminary analyses to differ between groups.</p></sec></sec><sec><title>Results</title><sec sec-type="intro"><title>Sample characteristics</title><p>Randomization produced an acceptable balance respecting group assignment by sample characteristics at baseline.<xref ref-type="bibr" rid="b17-hiv-2-027">17</xref> Of eligible families, 97% chose to participate. As planned, 40 dyads were randomized. However, two dyads were excluded from analyses due to withdrawal from the study prior to the start of Session 1. See <xref ref-type="fig" rid="f2-hiv-2-027">Figure 2</xref>. Data analyses were based on 38 dyads, using an intent-to-treat design, which included the 2 misallocated dyads. The characteristics of these 38 adolescents are presented in <xref ref-type="table" rid="t1-hiv-2-027">Table 1</xref>. There were no adverse events.</p></sec><sec><title>Plans and actions</title><p>FACE adolescents completed the Five Wishes<sup>&#x000a9;</sup> with their families at a higher rate than the HLC adolescents (90% versus 11%, <italic>P</italic> &#x0003c; 0.001; <xref ref-type="table" rid="t2-hiv-2-027">Table 2</xref>). At Baseline, one adolescent in the FACE group previously completed an AD and 5 were unsure whether they had. At 3-month post-intervention uncertainty was resolved. Five Wishes<sup>&#x000a9;</sup> completion did not significantly differ by gender, race, ethnicity, education, employment status, CDC stage of illness, number of guardians present, length of time with known diagnosis or age at diagnosis. However, teens whose surrogates were not biological family members (n = 8/10; 80%) were more likely to complete the Five Wishes<sup>&#x000a9;</sup> than those whose surrogates who were biological relatives (11/28; 40%, <italic>P</italic> = 0.031).</p></sec><sec><title>Decision to stop extraordinary treatment</title><p>On the Statement of Treatment Preferences the majority of adolescents chose to continue all treatments, regardless of quality of life. Ten percent of adolescents in Situation 1, 26% in Situation 2, and 24% in Situation 3 chose to discontinue extraordinary treatment. FACE adolescents appeared to be no more likely than HLC adolescents to discontinue treatment across the three situations, but the absence of statistical significance in this small sample is not absence of an effect. See <xref ref-type="table" rid="t2-hiv-2-027">Table 2</xref>. Non-African-American adolescents were significantly more likely to choose discontinue treatment (<italic>P</italic> = 0.026). A trend emerged for non-African-American adolescents to be more likely to discontinue treatment under Situation 2 (<italic>P</italic> = 0.060), if they were to become physically disabled and require nursing home care. No associations reached significance between the three Situations by gender, education, employment status, age, length of time known diagnosis or age learned HIV status.</p></sec><sec><title>Psychological adjustment</title><p>FACE adolescents who talked about their own prospective death and dying with their families in facilitated conversations by a trained facilitator were no more depressed or anxious than HLC adolescents at 3-months post-intervention (<xref ref-type="table" rid="t3-hiv-2-027">Table 3</xref>). Surrogates in the FACE group demonstrated slight increases in depressed and anxious mood compared to controls at 3-months post-intervention, controlling for baseline levels. However, increases were not clinically or statistically significant, but in minimal ranges and could be due to chance. Baseline levels of depression and anxiety predicted depression (adolescents, <italic>P</italic> = 0.002; surrogates, <italic>P</italic> &#x0003c; 0.001) and anxiety (adolescents, <italic>P</italic> = 0.003; surrogates <italic>P</italic> &#x0003c; 0.001) at 3-months post-intervention. Overall, adjusted mean levels of adolescent and surrogate depression and anxiety (<xref ref-type="table" rid="t3-hiv-2-027">Table 3</xref>) at 3-month post-intervention fell in the minimal clinical range. Depression and anxiety at 3-month post-intervention, controlling for baseline, did not differ significantly by gender, race, ethnicity, education, employment status, age at diagnosis, length of time with known diagnosis, family type or number of guardians present. Adolescents assigned to the intervention had statistically significantly higher depressed mood compared to controls at baseline, although mood levels were clinically insignificant in the minimal range.</p></sec><sec><title>Quality of life</title><p>Quality of life as measured by the PedsQL<sup>&#x02122;</sup> Total score was maintained for adolescents in both FACE and HLC and there were not significant differences by group or on any of the subscales (<xref ref-type="table" rid="t4-hiv-2-027">Table 4</xref>).</p><p>However, surrogates&#x02019; perception of their adolescents&#x02019; Total quality of life was significantly lower for surrogates in the FACE versus HLC group (<italic>P</italic> = 0.032) at 3-months, controlling for baseline levels. FACE surrogates rated their adolescents as having poorer <italic>school</italic> quality of life at 3-months post-intervention (66.9 versus 80.0, <italic>P</italic> = 0.011) and poorer <italic>emotion</italic> quality of life (74.8 versus 85.7, <italic>P</italic> = 0.029), compared to HLC surrogates. The <italic>physical</italic> and <italic>social</italic> subscale scores were not significantly different by group, controlling for baseline levels.</p></sec><sec><title>Quality of life &#x02013; HIV specific symptoms</title><p>On the GHAC trends towards more HIV-specific symptoms emerged in FACE vs HLC adolescents for the following symptoms (See <xref ref-type="table" rid="t5-hiv-2-027">Table 5</xref>): rash or itching; fatigue or weakness; and trouble sleeping. However, the scores reflect very low levels of symptoms, if examined using the midpoint cut-off for reporting symptoms which distressed them, moderately, very much or extremely. There were no statistically significant differences between FACE and HLC teens for any other HIV related symptoms 3-months post-intervention. There also was no relationship between Treatment Preferences and symptom score (<italic>P</italic> = 0.39).</p><p>In secondary analysis using a regression model examining all adolescents regardless of treatment arm, those in CDC Category B (symptomatic, not AIDS) had lower physical scores (more symptoms) than those in Category A (asymptomatic) or C (AIDS) (<italic>P</italic> = 0.005) and they scored higher on Total Symptoms (<italic>P</italic> = 0.015).</p></sec></sec><sec><title>Discussion</title><p>Using a rigorous randomized 2-arm design and intent-to-treat analysis, the FACE intervention demonstrated that advance care planning can be safely administered to HIV+ teens, ie, did not cause significant emotional distress or adverse events. FACE prepared surrogate decision makers for their role in EOL discussions and treatment decisions.</p><p>Our study challenges earlier findings<xref ref-type="bibr" rid="b38-hiv-2-027">38</xref>&#x02013;<xref ref-type="bibr" rid="b47-hiv-2-027">47</xref> with 100% of our primarily African-American FACE group completing an advance directive. The fact that several families spontaneously requested an extra copy of the Five Wishes<sup>&#x000a9;</sup> to complete for themselves suggests this outcome was not a result of the Hawthorne Effect (desire to please the researcher). Our results are consistent with a report by Washington, who in a study of African-American primary caregivers who made decisions about EOL care, found strong support for hospice care.<xref ref-type="bibr" rid="b48-hiv-2-027">48</xref></p><p>Participating in the FACE intervention did not influence decisions to discontinue treatment. Our goal was to safely assist adolescents with HIV/AIDS to make decisions with their families about their EOL preferences, while still cognitively intact.<xref ref-type="bibr" rid="b49-hiv-2-027">49</xref>&#x02013;<xref ref-type="bibr" rid="b51-hiv-2-027">51</xref> People sometimes change their AD as the disease progresses, for example, deciding to &#x0201c;Allow a Natural Death,&#x0201d; rather than to continue aggressive treatment(s). Thus, EOL care decision making is best under-stood as an ongoing process, rather than a one-time event, and should be revisited.<xref ref-type="bibr" rid="b52-hiv-2-027">52</xref>&#x02013;<xref ref-type="bibr" rid="b57-hiv-2-027">57</xref></p><p>Consistent with earlier adult studies<xref ref-type="bibr" rid="b44-hiv-2-027">44</xref>,<xref ref-type="bibr" rid="b45-hiv-2-027">45</xref>,<xref ref-type="bibr" rid="b58-hiv-2-027">58</xref>&#x02013;<xref ref-type="bibr" rid="b61-hiv-2-027">61</xref> African-American adolescents in our cohort preferred to continue all treatments at EOL at rates significantly higher than non-African-American adolescents, however, because of our small sample size this result may not be stable. This finding differs from that of Hinds and colleagues<xref ref-type="bibr" rid="b62-hiv-2-027">62</xref> who reported race did not influence DNR (do not resuscitate) status in a pediatric oncology sample. This difference could be due to the timing of decision making, which in the Hinds study was during what Hansen<xref ref-type="bibr" rid="b5-hiv-2-027">5</xref> calls the &#x0201c;central period&#x0201d; of decision making (where EOL is eminent), rather than the &#x0201c;antecedent period&#x0201d; as was done in our study. Our African-American families were willing to think and talk about EOL issues and were prepared for their role as decision-makers.<xref ref-type="bibr" rid="b17-hiv-2-027">17</xref>,<xref ref-type="bibr" rid="b18-hiv-2-027">18</xref></p><p>FACE achieved rates of recruitment in excess of those reported in adults in which only 30%&#x02013;47% of eligible patients participated in EOL studies.<xref ref-type="bibr" rid="b63-hiv-2-027">63</xref>&#x02013;<xref ref-type="bibr" rid="b66-hiv-2-027">66</xref> Nevertheless, 54% of potential participants approached prior to screening for eligibility, declined to participate. Dyadic/family studies pose a challenge as sometimes the patient wants to participate, but the family member does not have time, wants to protect the patient, or is uninterested.<xref ref-type="bibr" rid="b67-hiv-2-027">67</xref></p><p>Several factors may explain the success of the FACE intervention. First, we integrated processes identified with successful HIV interventions,<xref ref-type="bibr" rid="b68-hiv-2-027">68</xref>&#x02013;<xref ref-type="bibr" rid="b70-hiv-2-027">70</xref> specifically, community-based participation in development and adaptation to ensure cultural sensitivity and to reduce health disparities.<xref ref-type="bibr" rid="b16-hiv-2-027">16</xref>,<xref ref-type="bibr" rid="b17-hiv-2-027">17</xref>,<xref ref-type="bibr" rid="b71-hiv-2-027">71</xref>,<xref ref-type="bibr" rid="b72-hiv-2-027">72</xref> Second, we used a competency-based program to ensure consistency in the delivery of the intervention as measured by two components: 1) facilitator certification and 2) patient and family ratings of quality of communication, consistent with the recommendations of Dickens.<xref ref-type="bibr" rid="b72-hiv-2-027">72</xref> Third, the high rate of retention suggests participants were highly motivated to seek education and improve long-term care. Fourth, FACE was highly family-centered. Finally, research assistants were hired and retained only if they committed to flexibility in scheduling sessions and if successfully certified (Respecting Choices<sup>&#x000ae;</sup> interview).</p><p>In contrast to Bakitas and colleagues,<xref ref-type="bibr" rid="b63-hiv-2-027">63</xref> we did not find improvements in quality of life or mood for the intervention group, rather healthy levels of mood and quality of life were maintained. Floor effects for mood and ceiling effects for quality of life limited the power to detect differences, and differences that we found were within healthy ranges and therefore not clinically significant. The reason(s) higher levels of depressed mood were found at baseline for adolescents randomly assigned to FACE versus HLC are unclear. Baseline assessment occurred before randomization, so assignment to the intervention group did not impact mood.</p><p>Unexpectedly, FACE surrogates perceived their adolescents&#x02019; school and emotional quality of life was lower compared to HLC surrogates. This may reflect increased knowledge of school related and emotional problems for their teens that emerged during the facilitated conversation. Also, FACE surrogates reported more sadness and anxiety at 3-month post-intervention, than FACE adolescents who reported less compared to baseline levels. Although the changes were not clinically or statistically significant, they suggest that adolescents may have found talking about their own death and dying less anxiety provoking and sad than their families did. This finding needs further study.</p></sec><sec><title>Conclusion</title><p>The FACE results begin to fill the gap on ethnocultural factors that influence EOL decision making and preferences among HIV-positive adolescents, who demonstrated a willingness to discuss difficult and emotionally-laden issues with their surrogate decision makers and complete advance directives, potentially &#x0201c;breaking the ice&#x0201d; for future EOL conversations. Going beyond measuring the effect of communication on satisfaction, we studied outcomes related to advance care planning, quality of life and mood using standardized measures. The FACE results suggest that research into this sensitive area is safe. Probable benefits at the time of dying for teens and families, or after death for families, remain to be demonstrated in future studies.</p></sec></body><back><ack><title>Acknowledgments</title><p>We wish to thank our families for their participation and the community for their help in developing this protocol, especially Ebony Johnson. We also thank Connie Trexler and Keith Selden who facilitated the community advisory boards and focus groups. We extend our gratitude to our research assistants who worked with our families: Stephanie Lee, Portia Pieterse, Yolanda Peele, Ellin Kao, LaQuisha Mark, Mackenzie Nowell, Megan Banet, Megan L Wilkins, Ericka Midgett, J Christopher Young, Elizabeth Kolivas. We thank Jennifer Marsh and Saeid Goudarzi for help with statistical support and data management early in the study. We thank our consultants Drs Beatrice Krauss, Mary Ann McCabe, Bruce Rapkin and Robert Washington who helped during the developmental phase of the study and Dr Tomas Silber for his ethics consultations. We thank the health care providers and case managers who referred families to our study, especially Drs Hans Spiegel and Natella Rakhmanina.</p></ack><fn-group><fn><p><bold>Funding/support</bold></p><p>The study was funded by grant 5R34MH072541-03 from the National Institute of Mental Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health. This trial has been registered at <ext-link ext-link-type="uri" xlink:href="www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> Identifier #NCT00723476.</p></fn><fn><p><bold>Disclosures</bold></p><p>Linda Briggs, receives royalties from the Respecting Choices<sup>&#x000ae;</sup> interview. However, the remaining authors have no financial relationships or other conflicts of interest relevant to this article to disclose.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-hiv-2-027"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Justice</surname><given-names>AC</given-names></name><name><surname>McGinnis</surname><given-names>KA</given-names></name><name><surname>Skanderson</surname><given-names>M</given-names></name><etal/></person-group><article-title>Towards a combined prognostic index for survival in HIV infection: the role of &#x02018;no-HIV&#x02019; biomarkers</article-title><source>HIV Med</source><year>2009</year><volume>11</volume><issue>2</issue><fpage>143</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">19751364</pub-id></element-citation></ref><ref id="b2-hiv-2-027"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McConnell</surname><given-names>MS</given-names></name><name><surname>Byers</surname><given-names>RH</given-names></name><name><surname>Frederick</surname><given-names>T</given-names></name><etal/></person-group><article-title>Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989&#x02013;2001</article-title><source>Epidemiology and Social Science</source><year>2005</year><volume>38</volume><issue>4</issue><fpage>488</fpage><lpage>494</lpage></element-citation></ref><ref id="b3-hiv-2-027"><label>3</label><element-citation publication-type="webpage"><collab>America&#x02019;s Children in Brief</collab><source>Key National Indicators of Well-Being</source><year>2008</year><comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.childstats.gov/americaschildren">http://www.childstats.gov/americaschildren</ext-link></comment></element-citation></ref><ref id="b4-hiv-2-027"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brady</surname><given-names>MT</given-names></name><name><surname>Oleske</surname><given-names>JM</given-names></name><name><surname>Williams</surname><given-names>PL</given-names></name><etal/></person-group><article-title>Declines in mortality and changes in causes of death in HIV-1 infected children during the HAART era</article-title><source>J Acquir Immune Defic Syndr</source><year>2010</year><issue>5391</issue><fpage>86</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">20035164</pub-id></element-citation></ref><ref id="b5-hiv-2-027"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>L</given-names></name><name><surname>Archbold</surname><given-names>PG</given-names></name><name><surname>Stewart</surname><given-names>BJ</given-names></name></person-group><article-title>Role strain and ease in decision-making to withdraw or withhold life support for elderly relatives</article-title><source>J Nurs Scholarsh</source><year>2004</year><volume>36</volume><issue>3</issue><fpage>233</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">15495492</pub-id></element-citation></ref><ref id="b6-hiv-2-027"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grady</surname><given-names>PA</given-names></name></person-group><article-title>Introduction: Papers from the National Institutes of Health State-of-the-Science Conference on improving end-of-life care</article-title><source>J Palliative Med</source><year>2005</year><volume>8</volume><issue>Suppl 1</issue><fpage>S1</fpage><lpage>S3</lpage></element-citation></ref><ref id="b7-hiv-2-027"><label>7</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bearison</surname><given-names>D</given-names></name></person-group><source>They Never Want to Tell You</source><publisher-loc>Cambridge, MA</publisher-loc><publisher-name>Harvard Univ Press</publisher-name><year>1991</year></element-citation></ref><ref id="b8-hiv-2-027"><label>8</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bluebond-Langner</surname><given-names>M</given-names></name></person-group><source>Private Worlds of Dying Children</source><publisher-loc>Princeton, NJ</publisher-loc><publisher-name>Princeton University Press</publisher-name><year>1978</year></element-citation></ref><ref id="b9-hiv-2-027"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinds</surname><given-names>PS</given-names></name><name><surname>Burghen</surname><given-names>EA</given-names></name><name><surname>Pritchard</surname><given-names>M</given-names></name></person-group><article-title>Conducting end-of-life studies in pediatric oncology</article-title><source>West J Nurs Res</source><year>2007</year><volume>29</volume><fpage>448</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">17538126</pub-id></element-citation></ref><ref id="b10-hiv-2-027"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinds</surname><given-names>PS</given-names></name><name><surname>Schum</surname><given-names>L</given-names></name><name><surname>Baker</surname><given-names>JN</given-names></name><name><surname>Wolfe</surname><given-names>J</given-names></name></person-group><article-title>Key factors affecting dying children and their families</article-title><source>J Palliat Med</source><year>2006</year><volume>8</volume><fpage>S70</fpage><lpage>S78</lpage><pub-id pub-id-type="pmid">16499471</pub-id></element-citation></ref><ref id="b11-hiv-2-027"><label>11</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Field</surname><given-names>MJ</given-names></name><name><surname>Behrman</surname><given-names>RE</given-names></name></person-group><source>When Children Die: Improving palliative and end-of-life care for children and their families</source><publisher-loc>Washington, DC</publisher-loc><publisher-name>Institute of Medicine, National Academy Press</publisher-name><year>2002</year></element-citation></ref><ref id="b12-hiv-2-027"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh-Kelly</surname><given-names>CM</given-names></name><name><surname>Lang</surname><given-names>KR</given-names></name><name><surname>Chevako</surname><given-names>J</given-names></name><etal/></person-group><article-title>Advance directives in a pediatric emergency department</article-title><source>Pediatrics</source><year>1999</year><volume>103</volume><fpage>826</fpage><lpage>830</lpage><pub-id pub-id-type="pmid">10103317</pub-id></element-citation></ref><ref id="b13-hiv-2-027"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyon</surname><given-names>ME</given-names></name><name><surname>McCabe</surname><given-names>MA</given-names></name><name><surname>Patel</surname><given-names>K</given-names></name><name><surname>D&#x02019;Angelo</surname><given-names>LJ</given-names></name></person-group><article-title>What do adolescents want? An exploratory study regarding end-of-life decision-making</article-title><source>J Adolesc Health</source><year>2004</year><volume>35</volume><issue>6</issue><fpage>529 e1</fpage><lpage>e6</lpage><pub-id pub-id-type="pmid">15581537</pub-id></element-citation></ref><ref id="b14-hiv-2-027"><label>14</label><element-citation publication-type="journal"><collab>American Academy of Pediatrics: Committee on Bioethics and Committee on Hospital Care</collab><article-title>Palliative care for children</article-title><source>Pediatrics</source><year>2000</year><volume>106</volume><fpage>351</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">10920167</pub-id></element-citation></ref><ref id="b15-hiv-2-027"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kane</surname><given-names>JR</given-names></name></person-group><article-title>Pediatric palliative care moving forward: Empathy, competence, quality, and the need for systematic change</article-title><source>J Palliat Med</source><year>2006</year><volume>9</volume><fpage>847</fpage><lpage>849</lpage><pub-id pub-id-type="pmid">16910797</pub-id></element-citation></ref><ref id="b16-hiv-2-027"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogart</surname><given-names>LM</given-names></name><name><surname>Uyeda</surname><given-names>K</given-names></name></person-group><article-title>Community-based participatory research: Partnering with communities for effective and sustainable behavioral health interventions</article-title><source>Health Psychol</source><year>2009</year><volume>28</volume><issue>4</issue><fpage>391</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">19594261</pub-id></element-citation></ref><ref id="b17-hiv-2-027"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyon</surname><given-names>ME</given-names></name><name><surname>Garvie</surname><given-names>PA</given-names></name><name><surname>Briggs</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>D&#x02019;Angelo</surname><given-names>L</given-names></name><name><surname>McCarter</surname><given-names>R</given-names></name></person-group><article-title>Development, feasibility and acceptability of the Family-Centered (FACE) Advance Care planning intervention for adolescents with HIV</article-title><source>J Palliat Med</source><year>2009</year><volume>12</volume><issue>4</issue><fpage>363</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">19327074</pub-id></element-citation></ref><ref id="b18-hiv-2-027"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyon</surname><given-names>ME</given-names></name><name><surname>Garvie</surname><given-names>PA</given-names></name><name><surname>McCarter</surname><given-names>R</given-names></name><name><surname>Briggs</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>D&#x02019;Angelo</surname><given-names>L</given-names></name></person-group><article-title>Who will speak for me? Improving end-of-life decision-making for adolescents with HIV and their families</article-title><source>Pediatrics</source><year>2009</year><volume>123</volume><issue>2</issue><fpage>e199</fpage><lpage>e206</lpage><pub-id pub-id-type="pmid">19171571</pub-id></element-citation></ref><ref id="b19-hiv-2-027"><label>19</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Leventhal</surname><given-names>HH</given-names></name><name><surname>Nerenz</surname><given-names>DR</given-names></name><name><surname>Steele</surname><given-names>DJ</given-names></name></person-group><article-title>Illness representations and coping with health threats</article-title><person-group person-group-type="editor"><name><surname>Baum</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>SE</given-names></name><name><surname>Singer</surname><given-names>JE</given-names></name></person-group><source>Handbook of Psychology and Health, Vol. IV: Social psychological aspects of health</source><publisher-loc>A New Jersey</publisher-loc><publisher-name>Laurence Erlbaum Associates, Inc</publisher-name><year>1984</year><fpage>219</fpage><lpage>252</lpage></element-citation></ref><ref id="b20-hiv-2-027"><label>20</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Leventhal</surname><given-names>H</given-names></name><name><surname>Diefenbach</surname><given-names>M</given-names></name></person-group><article-title>The active side of illness cognition</article-title><person-group person-group-type="editor"><name><surname>Skelton</surname><given-names>JA</given-names></name><name><surname>Croyle</surname><given-names>RT</given-names></name></person-group><source>Mental Representation in Health and Illness</source><publisher-loc>New York, NY</publisher-loc><publisher-name>Springer Verlag</publisher-name><year>1991</year><fpage>247</fpage><lpage>272</lpage></element-citation></ref><ref id="b21-hiv-2-027"><label>21</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Leventhal</surname><given-names>H</given-names></name><name><surname>Benyamini</surname><given-names>Y</given-names></name><name><surname>Shafer</surname><given-names>C</given-names></name></person-group><article-title>Lay beliefs about health and illness</article-title><person-group person-group-type="editor"><name><surname>Ayers</surname><given-names>S</given-names></name></person-group><source>Cambridge Handbook of Psychology, Health and Medicine</source><publisher-loc>Cambridge, MA</publisher-loc><publisher-name>Cambridge University Press</publisher-name><year>2007</year><fpage>124</fpage><lpage>128</lpage></element-citation></ref><ref id="b22-hiv-2-027"><label>22</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lazarus</surname><given-names>RS</given-names></name><name><surname>Folkman</surname><given-names>S</given-names></name></person-group><source>Appraisal, and Coping</source><publisher-loc>New York, NY</publisher-loc><publisher-name>Springer Publishing Company</publisher-name><year>1984</year></element-citation></ref><ref id="b23-hiv-2-027"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Power</surname><given-names>C</given-names></name><name><surname>Selnes</surname><given-names>OA</given-names></name><name><surname>Grim</surname><given-names>JA</given-names></name><name><surname>McArthur</surname><given-names>JC</given-names></name></person-group><article-title>HIV Dementia Scale: a rapid screening test</article-title><source>J Acquir Immune Defic Syndr Hum Retrovirol</source><year>1995</year><volume>8</volume><fpage>273</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">7859139</pub-id></element-citation></ref><ref id="b24-hiv-2-027"><label>24</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>AT</given-names></name><name><surname>Steer</surname><given-names>RA</given-names></name></person-group><source>Beck Anxiety Inventory Manual</source><publisher-loc>San Antonio, TX</publisher-loc><publisher-name>The Psychological Corporation, Harcourt Brace &#x00026; Company</publisher-name><year>1993</year></element-citation></ref><ref id="b25-hiv-2-027"><label>25</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>AT</given-names></name><name><surname>Steer</surname><given-names>RA</given-names></name><name><surname>Brown</surname><given-names>GK</given-names></name></person-group><source>Beck Depression Inventory Manual</source><edition>2nd edition</edition><publisher-loc>San Antonio, TX</publisher-loc><publisher-name>The Psychological Corporation, Harcourt Brace &#x00026; Company</publisher-name><year>1996</year></element-citation></ref><ref id="b26-hiv-2-027"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>CA</given-names></name><name><surname>Katz</surname><given-names>SH</given-names></name><name><surname>Ghaziuddin</surname><given-names>N</given-names></name><name><surname>Brand</surname><given-names>E</given-names></name><name><surname>Hill</surname><given-names>E</given-names></name><name><surname>McGovern</surname><given-names>L</given-names></name></person-group><article-title>Diagnosis and assessment of depression and suicidality using the NIMH Diagnostic Interview Scale for Children-DISC-2.3-National Institute of Mental Health</article-title><source>J Abnormal Child Psych</source><year>1997</year><volume>25</volume><issue>3</issue><fpage>173</fpage><lpage>181</lpage></element-citation></ref><ref id="b27-hiv-2-027"><label>27</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Barkley</surname><given-names>RA</given-names></name></person-group><source>Attention-Deficit Hyperactivity Disorder: A clinical workbook</source><publisher-loc>New York, NY</publisher-loc><publisher-name>The Guilford Press</publisher-name><year>1993</year></element-citation></ref><ref id="b28-hiv-2-027"><label>28</label><element-citation publication-type="webpage"><collab>American Academy of Pediatrics</collab><source>Bright Futures</source><year>2005</year><date-in-citation>Accessed January 10, 2010</date-in-citation><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://brightfutures.aap.org/web/healthCareProfessionalstoolsAndResources.asp">http://brightfutures.aap.org/web/healthCareProfessionalstoolsAndResources.asp</ext-link></comment></element-citation></ref><ref id="b29-hiv-2-027"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf-Branigin</surname><given-names>M</given-names></name><name><surname>Schuyler</surname><given-names>V</given-names></name><name><surname>White</surname><given-names>P</given-names></name></person-group><article-title>Improving quality of life and career attitudes of youth with disabilities: Experiences from the Adolescent Employment Readiness Center</article-title><source>Res Soc Work Prac</source><year>2007</year><volume>17</volume><fpage>324</fpage><lpage>334</lpage></element-citation></ref><ref id="b30-hiv-2-027"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiener</surname><given-names>L</given-names></name><name><surname>Ballard</surname><given-names>E</given-names></name><name><surname>Brennan</surname><given-names>T</given-names></name><name><surname>Battles</surname><given-names>H</given-names></name><name><surname>Martinez</surname><given-names>P</given-names></name><name><surname>Pao</surname><given-names>M</given-names></name></person-group><article-title>How I wish to be remembered: the use of an advance care planning document in adolescent and young adult populations</article-title><source>J Palliat Med</source><year>2008</year><volume>11</volume><fpage>1309</fpage><lpage>1313</lpage><pub-id pub-id-type="pmid">19115889</pub-id></element-citation></ref><ref id="b31-hiv-2-027"><label>31</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hammes</surname><given-names>BJ</given-names></name><name><surname>Briggs</surname><given-names>L</given-names></name></person-group><article-title>Respecting choices: advance care planning facilitator manual</article-title><source>Includes Statement of Treatment Preferences</source><publisher-loc>La Crosse, WI</publisher-loc><publisher-name>Gundersen Lutheran Medical Foundation</publisher-name><year>2000</year></element-citation></ref><ref id="b32-hiv-2-027"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watcher</surname><given-names>RM</given-names></name><name><surname>Lo</surname><given-names>B</given-names></name></person-group><article-title>Advance directives for patients with Human Immunodeficiency Virus infection</article-title><source>Crit Care Clin</source><year>1993</year><volume>9</volume><fpage>125</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">8422613</pub-id></element-citation></ref><ref id="b33-hiv-2-027"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varni</surname><given-names>JW</given-names></name><name><surname>Seid</surname><given-names>M</given-names></name><name><surname>Rode</surname><given-names>CA</given-names></name></person-group><article-title>The PEDSQL: measurement model for the pediatric quality of life inventory</article-title><source>Med Care</source><year>1999</year><volume>37</volume><fpage>126</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">10024117</pub-id></element-citation></ref><ref id="b34-hiv-2-027"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varni</surname><given-names>JW</given-names></name><name><surname>Seid</surname><given-names>M</given-names></name><name><surname>Kurtin</surname><given-names>PS</given-names></name></person-group><article-title>PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations</article-title><source>Med Care</source><year>2001</year><volume>39</volume><fpage>800</fpage><lpage>812</lpage><pub-id pub-id-type="pmid">11468499</pub-id></element-citation></ref><ref id="b35-hiv-2-027"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varni</surname><given-names>JW</given-names></name><name><surname>Burwinkle</surname><given-names>TM</given-names></name><name><surname>Seid</surname><given-names>M</given-names></name><name><surname>Skarr</surname><given-names>D</given-names></name></person-group><article-title>The PedsQL<sup>TM</sup> 4.0 as a pediatric population health measure: Feasibility, reliability, and validity</article-title><source>Ambul Pediatr</source><year>2003</year><volume>3</volume><fpage>329</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">14616041</pub-id></element-citation></ref><ref id="b36-hiv-2-027"><label>36</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gortmaker</surname><given-names>SL</given-names></name><name><surname>Lenderking</surname><given-names>WR</given-names></name><name><surname>Clark</surname><given-names>C</given-names></name><etal/></person-group><article-title>Development and Use of a Pediatric Quality of Life Questionnaire in AIDS Clinical Trials: Reliability and Validity of the General Health Assessment for Children</article-title><person-group person-group-type="editor"><name><surname>Drotar</surname><given-names>D</given-names></name></person-group><source>Measuring Health-Related Quality of Life in Children and Adolescents: Implications for Research and Practice</source><publisher-loc>Mahway, NJ</publisher-loc><publisher-name>Lawrence Erlbaum Associates</publisher-name><year>1998</year><fpage>219</fpage><lpage>235</lpage></element-citation></ref><ref id="b37-hiv-2-027"><label>37</label><element-citation publication-type="journal"><collab>Centers for Disease Control and Prevention</collab><article-title>1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults</article-title><source>MMWR: Recomm Rep</source><year>1992</year><volume>41</volume><fpage>1</fpage><lpage>17</lpage></element-citation></ref><ref id="b38-hiv-2-027"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>RS</given-names></name><name><surname>Zayas</surname><given-names>LH</given-names></name><name><surname>Mulvihill</surname><given-names>M</given-names></name><name><surname>Baskin</surname><given-names>SA</given-names></name><name><surname>Meier</surname><given-names>DE</given-names></name></person-group><article-title>Barriers to completion of health care proxies: An examination of ethnic differences</article-title><source>Arch Intern Med</source><year>1998</year><volume>158</volume><fpage>2493</fpage><lpage>2497</lpage><pub-id pub-id-type="pmid">9855388</pub-id></element-citation></ref><ref id="b39-hiv-2-027"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackhall</surname><given-names>LJ</given-names></name><name><surname>Frank</surname><given-names>G</given-names></name><name><surname>Murphy</surname><given-names>ST</given-names></name><name><surname>Michel</surname><given-names>V</given-names></name><name><surname>Palmer</surname><given-names>JM</given-names></name><name><surname>Azen</surname><given-names>SP</given-names></name></person-group><article-title>Ethnicity and attitudes towards life sustaining technology</article-title><source>Soc Sci Med</source><year>1999</year><volume>48</volume><fpage>1779</fpage><lpage>1789</lpage><pub-id pub-id-type="pmid">10405016</pub-id></element-citation></ref><ref id="b40-hiv-2-027"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiely</surname><given-names>DK</given-names></name><name><surname>Mitchell</surname><given-names>SL</given-names></name><name><surname>Marlow</surname><given-names>A</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name><name><surname>Morris</surname><given-names>JN</given-names></name></person-group><article-title>Racial and state differences in the designation of advance directives in nursing home residents</article-title><source>J Am Geriatr Soc</source><year>2001</year><volume>49</volume><fpage>1346</fpage><lpage>1352</lpage><pub-id pub-id-type="pmid">11890494</pub-id></element-citation></ref><ref id="b41-hiv-2-027"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degenholtz</surname><given-names>HB</given-names></name><name><surname>Arnold</surname><given-names>RA</given-names></name><name><surname>Meisel</surname><given-names>A</given-names></name><name><surname>Lave</surname><given-names>JR</given-names></name></person-group><article-title>Persistence of racial disparities in advance care plan documents among nursing home residents</article-title><source>J Am Geriatr Soc</source><year>2002</year><volume>50</volume><fpage>378</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">12028224</pub-id></element-citation></ref><ref id="b42-hiv-2-027"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degenholtz</surname><given-names>HB</given-names></name><name><surname>Thomas</surname><given-names>SB</given-names></name><name><surname>Miller</surname><given-names>MJ</given-names></name></person-group><article-title>Race and the intensive care unit: Disparities in preferences for end-of-life care</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><issue>5 Suppl</issue><fpage>S373</fpage><lpage>S378</lpage><pub-id pub-id-type="pmid">12771586</pub-id></element-citation></ref><ref id="b43-hiv-2-027"><label>43</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>DB</given-names></name></person-group><source>Health Care Divided: Race and Healing a Nation</source><publisher-loc>Ann Arbor, MI</publisher-loc><publisher-name>The University of Michigan Press</publisher-name><year>2002</year><fpage>24</fpage><lpage>27</lpage></element-citation></ref><ref id="b44-hiv-2-027"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>RS</given-names></name><name><surname>Hamel</surname><given-names>MB</given-names></name><name><surname>Teno</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Patient race and decisions to withhold or withdraw life-sustaining treatments for seriously ill hospitalized adults. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment</article-title><source>Am J Med</source><year>2000</year><volume>108</volume><fpage>14</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">11059436</pub-id></element-citation></ref><ref id="b45-hiv-2-027"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krakauer</surname><given-names>EL</given-names></name><name><surname>Crenner</surname><given-names>C</given-names></name><name><surname>Fox</surname><given-names>K</given-names></name></person-group><article-title>Barriers to optimum end-of-life care for minority patients</article-title><source>J AM Geriatr Soc</source><year>2002</year><volume>50</volume><issue>1</issue><fpage>182</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">12028266</pub-id></element-citation></ref><ref id="b46-hiv-2-027"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawley</surname><given-names>LM</given-names></name></person-group><article-title>Racial, cultural and ethnic factors influencing end-of-life care</article-title><source>J Palliative Med</source><year>2005</year><volume>8</volume><fpage>S58</fpage><lpage>S69</lpage></element-citation></ref><ref id="b47-hiv-2-027"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyon</surname><given-names>ME</given-names></name><name><surname>Williams</surname><given-names>PL</given-names></name><name><surname>Woods</surname><given-names>ER</given-names></name><etal/></person-group><article-title>Do not resuscitate orders and/or hospice care, psychological health and quality of life among children/adolescents with AIDS</article-title><source>J Palliative Med</source><year>2008</year><volume>11</volume><fpage>459</fpage><lpage>469</lpage></element-citation></ref><ref id="b48-hiv-2-027"><label>48</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Washington</surname><given-names>R</given-names></name></person-group><article-title>Press Release: Study by former DC Commissioner of mental health finds hospice care benefits black families</article-title><source>Montgomery Hospice</source><month>6</month><day>24</day><year>2004</year><date-in-citation>Accessed January 10, 2010</date-in-citation><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.montgomeryhospice.org/pdfs/20040610.pdf">http://www.montgomeryhospice.org/pdfs/20040610.pdf</ext-link>. [June 24, 2004]</comment></element-citation></ref><ref id="b49-hiv-2-027"><label>49</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Allison</surname><given-names>S</given-names></name><name><surname>Wolters</surname><given-names>PL</given-names></name><name><surname>Brouwers</surname><given-names>P</given-names></name></person-group><article-title>Youth with HIV/AIDS: Neurobehavioral consequences</article-title><person-group person-group-type="editor"><name><surname>Paul</surname><given-names>RH</given-names></name><name><surname>Sachtor</surname><given-names>NC</given-names></name><name><surname>Valcour</surname><given-names>V</given-names></name><name><surname>Tashima</surname><given-names>KT</given-names></name></person-group><source>HIV and the Brain</source><publisher-loc>Totowa, NJ</publisher-loc><publisher-name>Current Clinical Neurology, Humana Press</publisher-name><year>2009</year><fpage>187</fpage><lpage>211</lpage></element-citation></ref><ref id="b50-hiv-2-027"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyon</surname><given-names>ME</given-names></name><name><surname>McCarter</surname><given-names>R</given-names></name><name><surname>D&#x02019;Angelo</surname><given-names>L</given-names></name></person-group><article-title>Detecting HIV associated neurocognitive disorders in adolescents: what is the best screening tool?</article-title><source>J Adolesc Health</source><year>2009</year><volume>44</volume><issue>2</issue><fpage>133</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">19167661</pub-id></element-citation></ref><ref id="b51-hiv-2-027"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>SM</given-names></name><name><surname>Shah</surname><given-names>SS</given-names></name><name><surname>Steenhoff</surname><given-names>AP</given-names></name><name><surname>Rutstein</surname><given-names>RM</given-names></name></person-group><article-title>The impact of AIDS diagnoses on long-term neurocognitive and psychiatric outcomes of surviving adolescents with perinatally acquired HIV</article-title><source>AIDS</source><year>2009</year><volume>23</volume><issue>14</issue><fpage>1859</fpage><lpage>1865</lpage><pub-id pub-id-type="pmid">19584705</pub-id></element-citation></ref><ref id="b52-hiv-2-027"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lautrette</surname><given-names>A</given-names></name><name><surname>Darmon</surname><given-names>M</given-names></name><name><surname>Megarbane</surname><given-names>B</given-names></name><etal/></person-group><article-title>A communication strategy and brochure for relatives of dying patients in the ICU</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><issue>5</issue><fpage>469</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">17267907</pub-id></element-citation></ref><ref id="b53-hiv-2-027"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lilly</surname><given-names>CM</given-names></name><name><surname>DeMeo</surname><given-names>DL</given-names></name><name><surname>Sonna</surname><given-names>LA</given-names></name><etal/></person-group><article-title>An intensive communication intervention for the critically ill</article-title><source>Am J Med</source><year>2000</year><volume>109</volume><issue>6</issue><fpage>469</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">11042236</pub-id></element-citation></ref><ref id="b54-hiv-2-027"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lilly</surname><given-names>CM</given-names></name><name><surname>Sonna</surname><given-names>LA</given-names></name><name><surname>Haley</surname><given-names>KJ</given-names></name><name><surname>Massaro</surname><given-names>AF</given-names></name></person-group><article-title>Intensive communication: four-year follow-up from a clinical practice study</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><issue>5</issue><fpage>S394</fpage><lpage>S399</lpage><pub-id pub-id-type="pmid">12771590</pub-id></element-citation></ref><ref id="b55-hiv-2-027"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romer</surname><given-names>AL</given-names></name><name><surname>Hammes</surname><given-names>BJ</given-names></name></person-group><article-title>Comunication, trust, and making choices: advance care planning four years on</article-title><source>J Palliat Med</source><year>2004</year><volume>7</volume><fpage>35</fpage><lpage>40</lpage></element-citation></ref><ref id="b56-hiv-2-027"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tulsky</surname><given-names>JA</given-names></name></person-group><article-title>Beyond advance directives: importance of communication skills at the end of life</article-title><source>JAMA</source><year>2005</year><volume>294</volume><issue>3</issue><fpage>395</fpage><lpage>365</lpage></element-citation></ref><ref id="b57-hiv-2-027"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tulsky</surname><given-names>JA</given-names></name></person-group><article-title>Interventions to enhance communication among patients, providers, and families</article-title><source>J Palliat Med</source><year>2005</year><volume>8</volume><fpage>S95</fpage><lpage>S102</lpage><pub-id pub-id-type="pmid">16499474</pub-id></element-citation></ref><ref id="b58-hiv-2-027"><label>58</label><element-citation publication-type="webpage"><collab>AARP</collab><article-title>AARP North Carolina End of Life Care Survey: African American Members</article-title><source>Report prepared by Rachelle Cummins, MA</source><year>2003</year><date-in-citation>Accessed on January 10, 2010</date-in-citation><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://research.aarp.org/">http://research.aarp.org/</ext-link></comment></element-citation></ref><ref id="b59-hiv-2-027"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>JS</given-names></name><name><surname>Weissman</surname><given-names>JS</given-names></name><name><surname>Cleary</surname><given-names>PD</given-names></name><etal/></person-group><article-title>Discussion of preferences for life-sustaining care by persons with AIDS</article-title><source>Arch Intern Med</source><year>1993</year><volume>153</volume><fpage>1241</fpage><lpage>1248</lpage><pub-id pub-id-type="pmid">8494476</pub-id></element-citation></ref><ref id="b60-hiv-2-027"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emanuel</surname><given-names>EJ</given-names></name><name><surname>Fairclough</surname><given-names>DL</given-names></name><name><surname>Emanuel</surname><given-names>L</given-names></name></person-group><article-title>Attitudes and desires related to euthanasia and physician-assisted suicide among terminally ill patients and their caregivers</article-title><source>JAMA</source><year>2000</year><volume>284</volume><fpage>2460</fpage><lpage>2468</lpage><pub-id pub-id-type="pmid">11074775</pub-id></element-citation></ref><ref id="b61-hiv-2-027"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>BL</given-names></name><name><surname>Lawson</surname><given-names>D</given-names></name><name><surname>Croughan-Minihane</surname><given-names>M</given-names></name><name><surname>Cooke</surname><given-names>M</given-names></name></person-group><article-title>Do patients&#x02019; ethnic and social factors influence the use of do-not-resuscitate orders?</article-title><source>Ethn Dis</source><year>1999</year><volume>9</volume><fpage>132</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">10355482</pub-id></element-citation></ref><ref id="b62-hiv-2-027"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>JN</given-names></name><name><surname>Rai</surname><given-names>S</given-names></name><name><surname>Lui</surname><given-names>W</given-names></name><etal/></person-group><article-title>Race does not influence Do-Not-Resuscitate Status or the number or timing of End-of-Life discussions at a pediatric oncology referral center</article-title><source>J Palliat Med</source><year>2009</year><volume>12</volume><issue>1</issue><fpage>71</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">19284266</pub-id></element-citation></ref><ref id="b63-hiv-2-027"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakitas</surname><given-names>M</given-names></name><name><surname>Lyons</surname><given-names>KD</given-names></name><name><surname>Hegel</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial</article-title><source>JAMA</source><year>2009</year><volume>302</volume><fpage>746</fpage><lpage>749</lpage></element-citation></ref><ref id="b64-hiv-2-027"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>B</given-names></name><name><surname>Reimer</surname><given-names>JC</given-names></name><name><surname>Brown</surname><given-names>P</given-names></name><name><surname>Martens</surname><given-names>N</given-names></name></person-group><article-title>Challenges of conducting research in palliative care</article-title><source>Omega (Westport)</source><year>1995</year><volume>31</volume><fpage>263</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">11660223</pub-id></element-citation></ref><ref id="b65-hiv-2-027"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudson</surname><given-names>P</given-names></name><name><surname>Aranda</surname><given-names>S</given-names></name><name><surname>McMurray</surname><given-names>N</given-names></name></person-group><article-title>Randomized controlled trials in palliative care: overcoming the obstacles</article-title><source>Int J Palliat Nurs</source><year>2001</year><volume>7</volume><fpage>427</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">11832846</pub-id></element-citation></ref><ref id="b66-hiv-2-027"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMillan</surname><given-names>SC</given-names></name><name><surname>Weitzner</surname><given-names>MA</given-names></name></person-group><article-title>Methodologic issues in collecting data from debilitated patients with cancer near the end of life</article-title><source>Oncol Nurs Forum</source><year>2003</year><volume>30</volume><fpage>123</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">12515990</pub-id></element-citation></ref><ref id="b67-hiv-2-027"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchhoff</surname><given-names>KT</given-names></name><name><surname>Kehl</surname><given-names>KA</given-names></name></person-group><article-title>Recruiting participants in end-of-life research</article-title><source>Am J Hosp Palliat Care</source><year>2008</year><volume>24</volume><fpage>515</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">17601835</pub-id></element-citation></ref><ref id="b68-hiv-2-027"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingram</surname><given-names>BL</given-names></name><name><surname>Flannery</surname><given-names>D</given-names></name><name><surname>Elkavich</surname><given-names>A</given-names></name><name><surname>Rotheram-Borus</surname><given-names>MJ</given-names></name></person-group><article-title>Common processes in evidence-based adolescent HIV prevention</article-title><source>Aids Behav</source><year>2008</year><volume>12</volume><fpage>374</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">18330687</pub-id></element-citation></ref><ref id="b69-hiv-2-027"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malow</surname><given-names>RM</given-names></name><name><surname>Kershaw</surname><given-names>T</given-names></name><name><surname>Sipsma</surname><given-names>H</given-names></name><name><surname>Rosenberg</surname><given-names>R</given-names></name><name><surname>Devieux</surname><given-names>JG</given-names></name></person-group><article-title>HIV preventive interventions for adolescents: A look back and ahead</article-title><source>Curr HIV/AIDS Rep</source><year>2007</year><volume>4</volume><fpage>173</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">18366948</pub-id></element-citation></ref><ref id="b70-hiv-2-027"><label>70</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tevendale</surname><given-names>HD</given-names></name><name><surname>Lightfoot</surname><given-names>M</given-names></name></person-group><article-title>Programs that work: Prevention for positives</article-title><person-group person-group-type="editor"><name><surname>Lyon</surname><given-names>ME</given-names></name><name><surname>D&#x02019;Angelo</surname><given-names>LJ</given-names></name></person-group><source>Teenagers HIV and AIDS: Insights from youths living with the virus</source><publisher-loc>Westport, CT</publisher-loc><publisher-name>Praeger Publishers</publisher-name><year>2006</year><fpage>105</fpage><lpage>126</lpage></element-citation></ref><ref id="b71-hiv-2-027"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyon</surname><given-names>ME</given-names></name><name><surname>Woodward</surname><given-names>K</given-names></name></person-group><article-title>Nonstigmatizing ways to engage HIV-positive African-American teens in mental health and supportive services: A commentary</article-title><source>J Natl Med Assoc</source><year>2003</year><volume>95</volume><fpage>196</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">12749679</pub-id></element-citation></ref><ref id="b72-hiv-2-027"><label>72</label><element-citation publication-type="book"><collab>US Department of Health and Human Services</collab><source>Call To Action: Eliminating racial and ethnic disparities in health</source><publisher-loc>Washington, DC</publisher-loc><publisher-name>Grantmakers in Health</publisher-name><year>1998</year></element-citation></ref><ref id="b73-hiv-2-027"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickens</surname><given-names>DS</given-names></name></person-group><article-title>Building competence in pediatric end-of-life care</article-title><source>J Palliative Med</source><year>2009</year><volume>12</volume><issue>7</issue><fpage>617</fpage><lpage>622</lpage></element-citation></ref></ref-list></back><floats-group><fig id="f1-hiv-2-027" position="float"><label>Figure 1</label><caption><p>Transactonal model of coping with stress.</p><p><bold>Notes:</bold> Proximal program mediators are shown in shaded areas.</p><p>Plans and Actions = statement of treatment preferences and completion of Five Wishes<sup>&#x000a9;</sup> advance directive.</p><p>Psychological Adjustment = Symptoms of depressed or anxious mood as measured by the Beck Depression Inventory II or the Beck Anxiety Inventory.</p><p>Quality of Life = Total, School, Emotion, Physical and Social quality of life as measured by PedsQL&#x02122;; HIV Specific Symptoms as measured by the General Health Assessment for Children.</p><p><bold>Abbreviations:</bold> A, adolescent; F, family; FACE, Family Centered Advance Care.</p></caption><graphic xlink:href="hiv-2-027f1"/></fig><fig id="f2-hiv-2-027" position="float"><label>Figure 2</label><caption><p>Flow of participants through each stage of the trial.</p><p><bold>Notes:</bold> *Kept in analysis, per intent-to-treat design, as if received allocated condition; **n = 1 randomized intervention adolescent became psychotic &#x00026; ineligible before Session 1; ***n = 1 randomized adolescent control was shot &#x00026; withdrew from study before Session 1.</p></caption><graphic xlink:href="hiv-2-027f2"/></fig><table-wrap id="t1-hiv-2-027" position="float"><label>Table 1</label><caption><p>3-month post-intervention characteristics for family centered (FACE) and healthy living control (HLC) adolescents with HIV/AIDS (n = 38)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Adolescent characteristics</th><th align="left" valign="top" rowspan="1" colspan="1">FACE intervention<break/>n = 20</th><th align="left" valign="top" rowspan="1" colspan="1">HLC group<break/>n = 18</th></tr></thead><tbody><tr><td colspan="3" align="left" valign="top" rowspan="1">Age (in years)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Mean (&#x000b1;SD)</td><td align="left" valign="top" rowspan="1" colspan="1">16.65 (&#x000b1;2.11)</td><td align="left" valign="top" rowspan="1" colspan="1">16.58 (&#x000b1;2.38)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Gender</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Males</td><td align="left" valign="top" rowspan="1" colspan="1">8 (40%)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (39%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Females</td><td align="left" valign="top" rowspan="1" colspan="1">12 (60%)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (61%)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Race/Ethnicity</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Black/African American</td><td align="left" valign="top" rowspan="1" colspan="1">17 (94%)</td><td align="left" valign="top" rowspan="1" colspan="1">18 (90%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Non-African American</td><td align="left" valign="top" rowspan="1" colspan="1">1 (6%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (10%)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Mode of HIV Transmission</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Perinatal infection</td><td align="left" valign="top" rowspan="1" colspan="1">15 (75%)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (61%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Behavioral infection</td><td align="left" valign="top" rowspan="1" colspan="1">5 (25%)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (39%)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">CDC classification<xref ref-type="bibr" rid="b1-hiv-2-027">1</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;A 1&#x02013;3 (asymptomatic)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (25%)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (61%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;B 1&#x02013;3 (symptomatic)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (30%)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (28%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;C 2&#x02013;3<xref ref-type="bibr" rid="b2-hiv-2-027">2</xref> (AIDS)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (45%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (11%)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Education</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No High School Diploma/in HS</td><td align="left" valign="top" rowspan="1" colspan="1">12 (60%)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (56%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;HS or GED equivalent</td><td align="left" valign="top" rowspan="1" colspan="1">4 (20%)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (33%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Some college/no bachelors</td><td align="left" valign="top" rowspan="1" colspan="1">4 (20%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (11%)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Income</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02264; Federal poverty line</td><td align="left" valign="top" rowspan="1" colspan="1">7 (35%)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (33%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;100%&#x02013;200% of Federal poverty line</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5%)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (17%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;201%&#x02013;300% of Federal poverty line</td><td align="left" valign="top" rowspan="1" colspan="1">4 (20%)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (22%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x0003e;300% of Federal poverty line</td><td align="left" valign="top" rowspan="1" colspan="1">6 (30%)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (17%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">2 (10%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (11%)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Housing status</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Permanently housed</td><td align="left" valign="top" rowspan="1" colspan="1">18 (90%)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (94%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Unstable living arrangement</td><td align="left" valign="top" rowspan="1" colspan="1">2 (10%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (6%)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Sexual orientation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Heterosexual</td><td align="left" valign="top" rowspan="1" colspan="1">17 (85%)</td><td align="left" valign="top" rowspan="1" colspan="1">15 (83%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Homosexual</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5.6%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Bisexual</td><td align="left" valign="top" rowspan="1" colspan="1">2 (10%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5.6%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Don&#x02019;t know</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5%)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Marital status</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Single</td><td align="left" valign="top" rowspan="1" colspan="1">19 (95%)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (94%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Married/Living</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Together</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (6%)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Length of time known diagnosis (in months)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">102.32 (&#x000b1;64.14)</td><td align="left" valign="top" rowspan="1" colspan="1">80.27 (&#x000b1;66.16)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Range</td><td align="left" valign="top" rowspan="1" colspan="1">11&#x02013;220</td><td align="left" valign="top" rowspan="1" colspan="1">3&#x02013;207</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Age learned HIV+ (in years)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">9.42 (&#x000b1;5.35)</td><td align="left" valign="top" rowspan="1" colspan="1">11.5 (&#x000b1;5.21)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Range</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x02013;18</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x02013;18</td></tr></tbody></table><table-wrap-foot><fn id="tfn21-hiv-2-027"><p><bold>Notes:</bold></p></fn><fn id="tfn1-hiv-2-027"><label>a</label><p>Data are from the old Centers for Disease Control and Prevention Classification system.<xref ref-type="bibr" rid="b37-hiv-2-027">37</xref></p></fn><fn id="tfn2-hiv-2-027"><label>b</label><p>No patient had category C1.</p></fn><fn id="tfn3-hiv-2-027"><p><bold>Abbreviations:</bold> CDC, Centers for Disease Control and Prevention; (1992); GED, general educational development; FACE, Family Centered Advance Care planning intervention; HLC, healthy living control for time and attention, matched comparison group; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-hiv-2-027" position="float"><label>Table 2</label><caption><p>3-month post-intervention outcomes: plans and actions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Outcomes</th><th align="left" valign="top" rowspan="1" colspan="1">FACE</th><th align="left" valign="top" rowspan="1" colspan="1">HLC</th><th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic><xref ref-type="table-fn" rid="tfn4-hiv-2-027">+</xref> value</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">FACE intervention</th><th align="left" valign="top" rowspan="1" colspan="1">HLC comparison</th><th align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1"><hr/></th><th align="left" valign="top" rowspan="1" colspan="1"><hr/></th><th align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">n = 20</th><th align="left" valign="top" rowspan="1" colspan="1">n = 18</th><th align="left" valign="top" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Completed Five Wishes or other AD</td><td align="left" valign="top" rowspan="1" colspan="1">19<xref ref-type="table-fn" rid="tfn8-hiv-2-027">a</xref> (95%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (11%)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tfn9-hiv-2-027">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Statement of Treatment Preferences:</td><td align="left" valign="top" rowspan="1" colspan="1">Stop all efforts<xref ref-type="table-fn" rid="tfn4-hiv-2-027">+</xref></td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Situation #1</td><td align="left" valign="top" rowspan="1" colspan="1">3 (15%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (6%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.187<xref ref-type="table-fn" rid="tfn8-hiv-2-027">a</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Situation #2</td><td align="left" valign="top" rowspan="1" colspan="1">5 (25%)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (28%)</td><td align="left" valign="top" rowspan="1" colspan="1">1.000<xref ref-type="table-fn" rid="tfn8-hiv-2-027">a</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Situation #3</td><td align="left" valign="top" rowspan="1" colspan="1">6 (30%)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (17%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.528<xref ref-type="table-fn" rid="tfn8-hiv-2-027">a</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn4-hiv-2-027"><label>+</label><p><bold>Notes:</bold> &#x0201c;To stop all efforts to keep me alive (For me quality of life is more important than length of life). This includes such treatments as CPR, blood transfusions, kidney dialysis and tube feedings.</p></fn><fn id="tfn5-hiv-2-027"><p>1. If I have serious complications from AIDS, such as an overwhelming infection or pneumonia, so that I was facing a long hospital stay, with many medical treatments AND my chance of living through this complication is low (for example, only 5 out of 100 kids will live), I would choose the following: (Whatever my choice, I want to be kept as comfortable as possible).</p></fn><fn id="tfn6-hiv-2-027"><p>2. If I have AIDS and a serious complication, such as an overwhelming infection or pneumonia and have a good chance of living through this complication, but it was expected that I would never be able to walk or talk again, and I would need 24 hour nursing care, I would choose the following. (Whatever my choice, I want to be kept as comfortable as possible).</p></fn><fn id="tfn7-hiv-2-027"><p>3. If I have AIDS and a serious complication, such as an overwhelming infection or pneumonia and have a good chance of living, but it was expected that I would never know who I was or who I was with and would need 24 hour nursing care, I would choose the following. (Whatever my choice, I want to be kept as comfortable as possible).</p></fn><fn id="tfn8-hiv-2-027"><label>a</label><p><bold>Notes:</bold> Data are frequencies. 1-sided Fisher Exact Test. 1 patient completed Five Wishes outside of one month post session window for protocol. No significant differences by perinatal vs behavioral transmission for completing advance directive, <italic>P</italic> = 0.284.</p></fn><fn id="tfn9-hiv-2-027"><label>*</label><p>Significant at the <italic>P</italic> = 0.05 level.</p></fn><fn id="tfn10-hiv-2-027"><p><bold>Abbreviations:</bold> CPR, cardiopulmonary resusication; FACE, Family Centered Advance Care Planning; EOL, end-of-life; HIV/AIDS, human immunodeficiency virus/acquired immune deficiency syndrome; HLC, healthy living control.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-hiv-2-027" position="float"><label>Table 3</label><caption><p>3-month post-intervention outcomes: psychological adjustment by treatment group controlling for baseline levels</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Outcomes</th><th align="left" valign="top" rowspan="1" colspan="1">FACE (n = 40)</th><th align="left" valign="top" rowspan="1" colspan="1">HLC (n = 36)</th><th align="left" valign="top" rowspan="1" colspan="1">P<sup>+</sup> value</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1"><hr/></th><th align="left" valign="top" rowspan="1" colspan="1"><hr/></th><th align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Intervention</th><th align="left" valign="top" rowspan="1" colspan="1">Comparison</th><th align="left" valign="top" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td colspan="4" align="left" valign="top" rowspan="1"><bold>BAI adjusted mean scores with upper and lower 95% confidence intervals (Range 0&#x02013;63; 0 to 7</bold> = <bold>minimal anxiety)</bold></td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Adolescent</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="left" valign="top" rowspan="1" colspan="1">2.76 (1.38&#x02013;4.60)</td><td align="left" valign="top" rowspan="1" colspan="1">1.38 (0.44&#x02013;2.84)</td><td align="left" valign="top" rowspan="1" colspan="1">0.170</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;3 month post-intervention</td><td align="left" valign="top" rowspan="1" colspan="1">2.48 (1.14&#x02013;4.34)</td><td align="left" valign="top" rowspan="1" colspan="1">1.06 (0.24&#x02013;2.45)</td><td align="left" valign="top" rowspan="1" colspan="1">0.149</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Surrogate&#x02019;s own mood</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="left" valign="top" rowspan="1" colspan="1">1.64 (0.62&#x02013;3.14)</td><td align="left" valign="top" rowspan="1" colspan="1">2.51 (1.14&#x02013;4.41)</td><td align="left" valign="top" rowspan="1" colspan="1">0.395</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;3 month post-intervention</td><td align="left" valign="top" rowspan="1" colspan="1">2.48 (1.20&#x02013;4.22)</td><td align="left" valign="top" rowspan="1" colspan="1">2.35 (1.06&#x02013;4.15)</td><td align="left" valign="top" rowspan="1" colspan="1">0.901</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1"><bold>BDI-II adjusted mean scores</bold><bold><sup>**</sup></bold><bold>with upper and lower 95% confidence intervals (range 0&#x02013;63; 0&#x02013;13</bold> = <bold>minimal depressed mood)</bold></td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Adolescent</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="left" valign="top" rowspan="1" colspan="1">7.8 (4.73&#x02013;11.69)</td><td align="left" valign="top" rowspan="1" colspan="1">1.27 (0.22&#x02013;3.17)</td><td align="left" valign="top" rowspan="1" colspan="1">0.001<sup>*</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;3 month post-intervention</td><td align="left" valign="top" rowspan="1" colspan="1">5.06 (2.57&#x02013;8.39)</td><td align="left" valign="top" rowspan="1" colspan="1">3.43 (1.35&#x02013;6.45)</td><td align="left" valign="top" rowspan="1" colspan="1">0.432</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Surrogate&#x02019;s own mood</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="left" valign="top" rowspan="1" colspan="1">2.0 (0.66&#x02013;4.09)</td><td align="left" valign="top" rowspan="1" colspan="1">3.65 (1.62&#x02013;6.50)</td><td align="left" valign="top" rowspan="1" colspan="1">0.261</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;3 month post-intervention</td><td align="left" valign="top" rowspan="1" colspan="1">2.73 (1.26&#x02013;4.77)</td><td align="left" valign="top" rowspan="1" colspan="1">3.29 (1.57&#x02013;5.65)</td><td align="left" valign="top" rowspan="1" colspan="1">0.676</td></tr></tbody></table><table-wrap-foot><fn id="tfn11-hiv-2-027"><p><bold>Abbreviations:</bold> BAI, Beck Anxiety Inventory; BDI-II, Beck Depression Inventory; 2nd Edition. Higher scores represent higher symptom levels. FACE, Family Centered Advance Care planning; HLC, healthy living control.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-hiv-2-027" position="float"><label>Table 4</label><caption><p>3-month post-intervention outcome: quality of life: PedsQL&#x02122; adjusted mean scores with 95% confidence intervals (ci upper and lower limits), controlling for baseline levels</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Outcomes</th><th align="left" valign="top" rowspan="1" colspan="1">FACE</th><th align="left" valign="top" rowspan="1" colspan="1">HLC</th><th align="left" valign="top" rowspan="1" colspan="1">P<xref ref-type="table-fn" rid="tfn13-hiv-2-027">+</xref> value</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Intervention</th><th align="left" valign="top" rowspan="1" colspan="1">Comparison</th><th align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">n = 40</th><th align="left" valign="top" rowspan="1" colspan="1">n = 36</th><th align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th colspan="2" align="left" valign="top" rowspan="1"><hr/></th><th align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Adjusted Mean/CI</th><th align="left" valign="top" rowspan="1" colspan="1">Adjusted Mean/CI</th><th align="left" valign="top" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td colspan="4" align="left" valign="top" rowspan="1">Adolescent</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TOTAL</td><td align="left" valign="top" rowspan="1" colspan="1">338.5 (321&#x02013;355)</td><td align="left" valign="top" rowspan="1" colspan="1">345.6 (327.3&#x02013;363.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.568</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Physical</td><td align="left" valign="top" rowspan="1" colspan="1">93.1 (89.4&#x02013;96.6)</td><td align="left" valign="top" rowspan="1" colspan="1">93.8 (91.3&#x02013;96.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.692</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;School</td><td align="left" valign="top" rowspan="1" colspan="1">75.0 (68.4&#x02013;82.0)</td><td align="left" valign="top" rowspan="1" colspan="1">77.7 (70.7&#x02013;85.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.589</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Emotional</td><td align="left" valign="top" rowspan="1" colspan="1">82.0 (74.8&#x02013;88.6)</td><td align="left" valign="top" rowspan="1" colspan="1">82.5 (74.4&#x02013;90.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.921</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Social</td><td align="left" valign="top" rowspan="1" colspan="1">90.3 (86.5&#x02013;93.9)</td><td align="left" valign="top" rowspan="1" colspan="1">92.0 (88.6&#x02013;95.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.297</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Surrogate perception of adolescent quality of Life</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TOTAL</td><td align="left" valign="top" rowspan="1" colspan="1">324.8 (308.4&#x02013;340.4)</td><td align="left" valign="top" rowspan="1" colspan="1">349.3 (333.4&#x02013;364.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.032<xref ref-type="table-fn" rid="tfn12-hiv-2-027">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Physical</td><td align="left" valign="top" rowspan="1" colspan="1">92.3 (89.3&#x02013;95.1)</td><td align="left" valign="top" rowspan="1" colspan="1">93.0 (89.7&#x02013;96.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.692</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;School</td><td align="left" valign="top" rowspan="1" colspan="1">66.9 (60.0&#x02013;74.1)</td><td align="left" valign="top" rowspan="1" colspan="1">80.0 (72.1&#x02013;88.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.018<xref ref-type="table-fn" rid="tfn12-hiv-2-027">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Emotion</td><td align="left" valign="top" rowspan="1" colspan="1">74.8 (67.2&#x02013;81.6)</td><td align="left" valign="top" rowspan="1" colspan="1">85.7 (78.9&#x02013;92.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.029<xref ref-type="table-fn" rid="tfn12-hiv-2-027">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Social</td><td align="left" valign="top" rowspan="1" colspan="1">91.0 (88.0&#x02013;93.8)</td><td align="left" valign="top" rowspan="1" colspan="1">92.7 (89.2&#x02013;95.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0.297</td></tr></tbody></table><table-wrap-foot><fn id="tfn32-hiv-2-027"><p><bold>Notes:</bold></p></fn><fn id="tfn12-hiv-2-027"><label>*</label><p>Significant at <italic>P</italic> = 0.05.</p></fn><fn id="tfn13-hiv-2-027"><label>+</label><p>All <italic>P</italic> values control for baseline using a <italic>t</italic>-test to assess significance. Range of subscale scores is 0 to 100. Higher scores represent better quality of life.</p></fn><fn id="tfn14-hiv-2-027"><p><bold>Abbreviations:</bold> FACE, Family Centered Advance Care planning; HLC, healthy living control.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5-hiv-2-027" position="float"><label>Table 5</label><caption><p>3-month post-intervention outcomes: quality of life-HIV specific symptoms: general health assessment for children HIV symptoms. Percentage of adolescents reporting moderately, very much or extremely distressed by symptom at 3-month post-intervention controlling for baseline levels of symptoms</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">HIV specific symptoms</th><th align="left" valign="top" rowspan="1" colspan="1">FACE intervention<break/>n = 20</th><th align="left" valign="top" rowspan="1" colspan="1">HLC comparison<break/>n = 18</th><th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Physical/bodily pain</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0.210</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Coughing/Wheezing</td><td align="left" valign="top" rowspan="1" colspan="1">10%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0.604</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nausea/vomiting</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0.737</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Skin problems (rash, itching, etc)</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0.063<xref ref-type="table-fn" rid="tfn15-hiv-2-027">+</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fatigue</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">0.095<xref ref-type="table-fn" rid="tfn15-hiv-2-027">+</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Feeling dizzy/lightheaded</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0.178</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fever/night sweats/shaking/chills</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0.737</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Loss of appetite</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0.663</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Trouble sleeping</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0.058<xref ref-type="table-fn" rid="tfn15-hiv-2-027">+</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Eye trouble/problems with vision</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">0.734</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Headaches</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0.342</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dry or painful mouth/trouble swallowing</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chest pain or tightness</td><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Difficulty breathing or catching breath</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0.656</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Runny nose/sinus trouble</td><td align="left" valign="top" rowspan="1" colspan="1">10%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0.479</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Muscle aches/joint or bone pain</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0.232</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pain, numbness or tingling</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0.792</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Overall discomfort</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1">0.697</td></tr></tbody></table><table-wrap-foot><fn id="tfn15-hiv-2-027"><label>+</label><p><bold>Notes:</bold> All <italic>P</italic> values control for baseline using a <italic>t</italic>-test to assess significance at the 0.05 level.</p></fn><fn id="tfn16-hiv-2-027"><p><bold>Abbreviations:</bold> FACE, Family Centered Advance Care planning; EOL, end-of-life; HIV/AIDS, human immunodeficiency virus/acquired immune deficiency syndrome; HLC, healthy living control.</p></fn></table-wrap-foot></table-wrap></floats-group></article>